The trial is positioned within a niche market for AML patients harboring p53 mutations, a subgroup with historically poor prognosis and limited treatment options. The combination therapy could provide a competitive edge against existing treatments, particularly if it demonstrates improved efficacy in relapse-free survival and overall survival. Given the FDA approval status of Decitabine and ATO for other indications, the potential for expedited regulatory pathways exists. The trial's success could lead to significant market opportunities in hematologic malignancies, especially for patients with mp53 mutations, which are often excluded from standard therapies.